Talbird SE, Anderson SA, Nossov M, Beattie N, Rak AT, Diaz-Mitoma F. Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis b in adults in the United States. Vaccine. 2023 May 26;41(23):3506-17. doi: 10.1016/j.vaccine.2023.04.022
Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9. doi: 10.1016/j.vaccine.2022.11.036
Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022 Jan 24;40(3):483-93. doi: 10.1016/j.vaccine.2021.12.002
Carrico J, Talbird SE, La EM, Poston S, Poirrier JE, DeMartino JK, Hogea C. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Vaccine. 2021 Aug 23;39(36):5187-97. doi: 10.1016/j.vaccine.2021.07.029
La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021 May 6;39(19):2660-7. doi: 10.1016/j.vaccine.2021.03.071
Aris E, Montourcy M, Esterberg E, Kurosky SK, Poston S, Hogea C. The adult vaccination landscape in the United States during the Affordable Care Act era: results from a large retrospective database analysis. Vaccine. 2020 Mar;38(14):2984-94. doi: 10.1016/j.vaccine.2020.02.057
McGrath LJ, Layton JB, Krueger WS, Kshirsagar AV, Butler AM. High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010-2013. Vaccine. 2018 Oct 1;36(41):6087-94. doi: 10.1016/j.vaccine.2018.08.079
Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018 Aug 9;36(33):5037-45. doi: 10.1016/j.vaccine.2018.07.005
Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine. 2015 Mar 10;33(11):1313-6. doi: 10.1016/j.vaccine.2015.01.069
Talbird S, Knerer G, Hausdorff W, Taylor T, Frostad CR. Reply to Strutton et al.: response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries”. Vaccine. 2011 Oct 1;29(44):7591-2.
Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine. 2010 Nov 19;28(Suppl 6):G14-22.
Talbird SE, Taylor TN, Knoll S, Frostad CR, Marti SG. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010 Nov 19;28(Suppl 6):G23-9.
Talbird SE, Ismaila AS, Taylor TN. A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine. 2010 Nov 19;28(Suppl 6):G3-G13.
Standaert B, Demarteau N, Talbird S, Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine. 2010 Nov 19;28(Suppl 6):G30-8.
Brown DS, Johnson FR, Poulos C, Messonnier ML. Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine. 2010 Feb 1;28(7):1702-8.
Lauria DT, Maskery B, Poulos C, Whittington D. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine. 2009 Mar 4;27(10):1609-21.
Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, Anh DD, Agtini M, Bhuttai Z, DOMI Typhoid Economics Study Group . The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine. 2008 Nov 25;26(50):6305-16.